Popular Diabetes Drug Turns Intestines into a 'Filter' for Glucose
A recent study conducted by researchers at Northwestern University in the United States has revealed a pivotal shift in understanding how metformin, the most widely used and popular treatment for type 2 diabetes worldwide, works. According to results published in specialized scientific journals, the drug primarily targets Complex I of the mitochondria within the cells lining the intestines, rather than the liver, as doctors and scientists had believed for decades. This discovery transforms the intestines into a vital filter that efficiently absorbs glucose from the bloodstream.
The prevailing medical view previously assumed that the drug worked by inhibiting glucose production in the liver. However, this theory faced a concentration issue: metformin reaches very high levels in the gastrointestinal tract, while its concentrations in the liver are far too low to produce such a significant effect. Through genetic engineering on laboratory models, researchers demonstrated that when intestinal mitochondria are protected from the drug’s effects, metformin completely loses its ability to lower blood sugar levels, even though it still reaches the liver.
Since inhibiting intestinal mitochondria reduces energy production within intestinal cells, these cells are forced to seek alternative sources to survive. This drives them to absorb large amounts of sugar from the bloodstream. These sugar molecules are then converted into other vital compounds, such as lactate and alpha-ketophenylalanine, which directly contribute to suppressing appetite, alongside stimulating the secretion of the hormone “GDF-15,” which sends signals to the brain to reduce the desire to eat.
Based on these scientific findings, which are reshaping the approach to diabetes treatments, the key points of the discovery can be summarized in the following dimensions:
• Metformin directly targets intestinal cells rather than primarily focusing on the liver.
The research medical team believes that understanding this intestinal mechanism opens future prospects for developing treatments specifically targeted at the gastrointestinal system, without the need for the drug to spread throughout the entire body. This approach would reduce side effects and increase the efficiency of controlling diabetes.
